Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse J Smith

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
BMC Systems Biology|March 17, 2009
Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivoJesse J Smith, Renée Deehan Kenney, David J Gagne, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Cancer Cell|July 12, 2011
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Genes & Development|July 3, 2010
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBPAmy K Walker, Fajun Yang, Karen Jiang, et al.
Nature|November 30, 2007
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetesJill C Milne, Philip D Lambert, Simon Schenk, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
BMC Systems Biology|March 17, 2009
Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivoJesse J Smith, Renée Deehan Kenney, David J Gagne, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 InhibitorLorna H Mitchell, P Ann Boriack-Sjodin, Sherri Smith, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Cancer Cell|July 12, 2011
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorScott R Daigle, Edward J Olhava, Carly A Therkelsen, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Genes & Development|July 3, 2010
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBPAmy K Walker, Fajun Yang, Karen Jiang, et al.
Nature|November 30, 2007
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetesJill C Milne, Philip D Lambert, Simon Schenk, et al.
Plos One|June 2, 2018
Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferationMichael J Thomenius, Jennifer Totman, Darren Harvey, et al.
Nature Chemical Biology|April 28, 2015
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsElayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, et al.
Cancer Cell|July 2, 2019
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossAndrew Fedoriw, Satyajit R Rajapurkar, Shane O'Brien, et al.
Pageof 4